What to Expect: Nurtec ODT, Ubrelvy, Qulipta & Zavzpret
You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!
Key Questions
- ¿Qué son los antagonistas de receptores de pequeñas moléculas de CGRP (gepantes)?
- ¿Cómo se diferencian los gepantes de los anticuerpos monoclonales de CGRP?
- ¿En qué etapa de un ataque de migraña se debe tomar un gepante?¿Qué gepantes están disponibles actualmente y en qué se diferencian entre sí?
- ¿Cuáles son las dosis y la administración para cada gepante?
- ¿Cómo decide un médico qué gepante probar para cada paciente?
- ¿En qué se diferencian los gepantes de los triptanes?
- ¿Cuáles son algunas otras opciones para pacientes que no responden a los gepantes?
- ¿Son efectivos los gepantes tanto para la migraña episódica como crónica?
- ¿Se pueden tomar gepantes durante el embarazo o la lactancia?
- ¿Existen interacciones medicamentosas y/o riesgos asociados con los gepantes?
- ¿Se pueden usar los gepantes para tratar la migraña en niños o adolescentes?
Interview Notes
- New York State Neurological Society
- American Headache Society
- Weill Cornell School of Medicine
- NewYork Presbyterian Hospital
- X (Twitter): @mrobbinsmd
- Press Release: “First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention”
- Study: “Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: Results from a randomized, controlled clinical trial”
- MWS Interview: “Planning for Pregnancy With Migraine”
Treatments Mentioned
- Antibiotics
- Antifungal medications
- Celecoxib (Elyxyb)
- Atogepant (Qulipta)
- CGRP Inhibitors
- CGRP monoclonal antibodies (mAbs)
- CGRP small-molecule receptor antagonists (gepants)
- Diclofenac (Cambia)
- Dihydroergotamine (DHE and Trudhesa)
- Galcanezumab (Emgality)
- Lasmiditan (Reyvow)
- Neuromodulation devices
- Nirmatrelvir/ritonavir (Paxlovid)
- Rimegepant (Nurtec)
- Triptans
- Ubrogepant (Ubrelvy)
- Zavegepant (Zavzpret)
Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.
This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.
Matthew Robbins, MD
Associate Professor of Neurology and Residency Program Director
Weill Cornell Medicine, NewYork-Presbyterian Hospital
Matthew S. Robbins, M.D., is the program director for the neurology residency and an associate professor of neurology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. His clinical practice focuses on patients with migraine, cluster headache, new daily persistent headache, other headache disorders, CSF (cerebrospinal fluid) leaks, and visual snow. He has experience with patient care, teaching, and research for headache disorder treatments, including monoclonal antibodies, procedures such as botulinum toxin injections and peripheral nerve blocks, and neuromodulation devices. Dr. Robbins developed an academic career integrating patient care, education and mentorship, research, and advocacy for people with headache and other neurological conditions.
Previously, Dr. Robbins earned his B.S. from Yale University and his M.D. from SUNY-Downstate College of Medicine. He completed his neurology residency at the Albert Einstein College of Medicine/Montefiore Medical Center, where he was also a chief resident and then a Fellow in Headache Medicine at the Montefiore Headache Center. He served on the faculty at Montefiore-Einstein for nearly a decade, where he was an associate professor of neurology, chief of neurology at the Jack D. Weiler Hospital, and director of inpatient services for the Montefiore Headache Center.
He serves as president-elect of the NewYork Neurological Society and on the board of directors of the American Headache Society. In addition, he is passionate about advocacy, and is a graduate of the Palatucci Advocacy Leadership Forum of the American Academy of Neurology.
Purchase full access to the entire 2024 Summit. Includes:
- All expert interviews with separate audio (MP3) files & transcripts
- Lifetime on-demand access with no annual fee to 2024 Summit
- Interview Summaries
- Treatment Guidelines
- And much more!
Related Talks for: Day 4 (2024)
New Daily Persistent Headache: Pain That Won’t Stop
Andrew D. Hershey, MD, PhD, FAAN, FAHS
The Nervous System, Stored Trauma & Migraine
Aimie Apigian, MD, MS, MPH
When Headache Starts Behind the Eyes
Deborah Friedman, MD, MPH, FAAN, FAHS
Enjoy a one-page summary of the key facts and insights from every interview. Save time and discover the important and essential points quickly. Available when you purchase a VIP Pass.
